Antibody-based therapeutics to watch in 2011.

Dual targeting strategies with bispecific antibodies. MAbs (2012) 2.13

6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland. MAbs (2011) 1.61

Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med (2012) 1.44

Antibodies to watch in 2015. MAbs (2015) 1.28

Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn. AAPS J (2012) 1.27

Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol (2012) 1.26

Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease. ACS Chem Biol (2012) 1.17

Antibodies to watch in 2014. MAbs (2013) 1.14

Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. J Immunol (2014) 1.13

Antibodies to watch in 2013: Mid-year update. MAbs (2013) 1.13

Monoclonal antibodies and toxins--a perspective on function and isotype. Toxins (Basel) (2012) 1.09

Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem (2012) 1.09

Expression of recombinant antibodies. Front Immunol (2013) 1.06

Soluble monomeric IgG1 Fc. J Biol Chem (2012) 1.06

Immunoconjugates and long circulating systems: origins, current state of the art and future directions. Adv Drug Deliv Rev (2012) 1.05

Biosimilar, biobetter and next generation therapeutic antibodies. MAbs (2011) 1.05

Vedolizumab for the treatment of ulcerative colitis and Crohn's disease. Immunotherapy (2012) 1.04

Size-Exclusion Chromatography for the Analysis of Protein Biotherapeutics and their Aggregates. J Liq Chromatogr Relat Technol (2012) 1.04

Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on. Cancer Immun (2012) 0.98

Galactosylation variations in marketed therapeutic antibodies. MAbs (2012) 0.96

IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of the Antibody Society. December 5-9, 2010, San Diego, CA USA. MAbs (2011) 0.93

New and emerging treatments for ulcerative colitis: a focus on vedolizumab. Biologics (2013) 0.90

The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC). Onco Targets Ther (2012) 0.89

An innovative approach for the characterization of the isoforms of a monoclonal antibody product. MAbs (2011) 0.89

Protein particulate detection issues in biotherapeutics development--current status. AAPS PharmSciTech (2012) 0.88

Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics. J Biol Chem (2013) 0.88

7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland. MAbs (2012) 0.88

Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins (Basel) (2011) 0.87

Therapeutic antibodies against cancer. Hematol Oncol Clin North Am (2012) 0.87

Molecular engineering of antibodies for therapeutic and diagnostic purposes. MAbs (2012) 0.87

HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy. J Cancer (2011) 0.86

A novel approach for the simultaneous quantification of a therapeutic monoclonal antibody in serum produced from two distinct host cell lines. MAbs (2012) 0.85

Antibodies to watch in 2017. MAbs (2016) 0.85

Computational design of protein-ligand interfaces: potential in therapeutic development. Trends Biotechnol (2011) 0.85

Adjuvant-free immunization with hemagglutinin-Fc fusion proteins as an approach to influenza vaccines. J Virol (2010) 0.85

The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigen. MAbs (2013) 0.85

Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages. J Biol Chem (2012) 0.85

Generation and characterization of a unique reagent that recognizes a panel of recombinant human monoclonal antibody therapeutics in the presence of endogenous human IgG. MAbs (2013) 0.84

A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells. MAbs (2014) 0.84

Pathways towards an effective immunotherapy for Parkinson's disease. Expert Rev Neurother (2011) 0.84

High-throughput method development for sensitive, accurate, and reproducible quantification of therapeutic monoclonal antibodies in tissues using orthogonal array optimization and nano liquid chromatography/selected reaction monitoring mass spectrometry. Anal Chem (2012) 0.84

Cells and cell lysates: a direct approach for engineering antibodies against membrane proteins using yeast surface display. Methods (2012) 0.84

Low level sequence variant analysis of recombinant proteins: an optimized approach. PLoS One (2012) 0.83

IgE immunotherapy: a novel concept with promise for the treatment of cancer. MAbs (2014) 0.83

Generation and analysis of the improved human HAL9/10 antibody phage display libraries. BMC Biotechnol (2015) 0.83

Comparison of the in vitro and in vivo stability of a succinimide intermediate observed on a therapeutic IgG1 molecule. MAbs (2013) 0.83

In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer. Oncol Rep (2013) 0.82

Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas. Br J Cancer (2013) 0.82

Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2m(1) antibody. MAbs (2014) 0.82

Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis. Recent Pat Biomed Eng (2012) 0.82

Pharmacokinetic/pharmacodynamic modeling in inflammation. Crit Rev Biomed Eng (2012) 0.81

Humanization of antibodies using heavy chain complementarity-determining region 3 grafting coupled with in vitro somatic hypermutation. J Biol Chem (2013) 0.81

Lonely killers: effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions. MAbs (2011) 0.80

Monoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin Drugs. Toxins (Basel) (2015) 0.79

Molecularly Targeted Therapy of Human Hepatocellular Carcinoma Xenografts with Radio-iodinated Anti-VEGFR2 Murine-Human Chimeric Fab. Sci Rep (2015) 0.78

Bispecific Antibody Conjugated Manganese-Based Magnetic Engineered Iron Oxide for Imaging of HER2/neu- and EGFR-Expressing Tumors. Theranostics (2016) 0.78

Tregalizumab - A Monoclonal Antibody to Target Regulatory T Cells. Front Immunol (2016) 0.78

Dual specificity of anti-CXCL10-CXCL9 antibodies is governed by structural mimicry. J Biol Chem (2011) 0.77

Identification of Eps15 as antigen recognized by the monoclonal antibodies aa2 and ab52 of the Wuerzburg Hybridoma Library against Drosophila brain. PLoS One (2011) 0.77

Flexible antibodies with nonprotein hinges. Proc Jpn Acad Ser B Phys Biol Sci (2011) 0.77

Target Therapy in Hematological Malignances: New Monoclonal Antibodies. Int Sch Res Notices (2014) 0.76

7th cancer scientific forum of theCancéropôle Lyon Auvergne Rhône-Alpes: March 20-21, 2012, Lyon, France. MAbs (2012) 0.76

Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA. MAbs (2014) 0.75

A high throughput capillary electrophoresis method to obtain pharmacokinetics and quality attributes of a therapeutic molecule in circulation. MAbs (2012) 0.75

Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease. J Nat Sci Biol Med (2016) 0.75

FAT1: a potential target for monoclonal antibody therapy in colon cancer. Br J Cancer (2016) 0.75

Novel antibody-based proteins for cancer immunotherapy. Cancers (Basel) (2011) 0.75

Electrospray ionization-ion mobility spectrometry identified monoclonal antibodies that bind exclusively to either the monomeric or a dimeric form of prostate specific antigen. Anal Chem (2012) 0.75

Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis. World J Gastroenterol (2015) 0.75

Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis. Expert Opin Drug Metab Toxicol (2016) 0.75

CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity. Oncol Lett (2017) 0.75

Targeted immunotherapy trials for idiopathic inflammatory myopathies. J Neurol (2012) 0.75

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med (2005) 10.16

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68

FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol (2007) 7.94

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology (2009) 5.94

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol (2010) 5.91

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood (2010) 3.69

Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer (2007) 3.67

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol (2010) 3.32

cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood (2003) 3.25

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol (2010) 3.06

Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol (2009) 2.97

Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell (2004) 2.71

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res (2009) 2.68

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia (2010) 2.65

Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol (2011) 2.62

Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res (2010) 2.20

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs (2010) 2.09

Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol (2010) 1.96

Antibodies to watch in 2010. MAbs (2010) 1.90

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol (2009) 1.84

Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs (2010) 1.83

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum (2007) 1.79

Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res (2010) 1.67

Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology (2010) 1.65

Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood (2010) 1.49

Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol (2010) 1.39

Catumaxomab: clinical development and future directions. MAbs (2011) 1.35

CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther (2010) 1.33

Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res (2010) 1.30

Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol (2010) 1.30

Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol (2010) 1.24

Metrics for antibody therapeutics development. MAbs (2010) 1.21

Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs (2010) 1.20

B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther (2010) 1.18

A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. J Thorac Oncol (2010) 1.16

Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood (2007) 1.14

Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res (2010) 1.14

A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology (2009) 1.13

A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res (2010) 1.12

A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol (2010) 1.08

CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction. Clin Exp Immunol (2010) 1.04

Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin. Clin Cancer Res (2011) 1.03

An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus (2009) 1.03

Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes. J Clin Pharmacol (2010) 0.96

A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity. Cancer Res (2007) 0.90

B-cell biology and related therapies in systemic lupus erythematosus. Rheum Dis Clin North Am (2010) 0.89

Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity. J Immunother (2010) 0.89

Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus. J Pharm Sci (2010) 0.85

Antibodies to watch in 2010. MAbs (2010) 1.90

Probabilities of success for antibody therapeutics. MAbs (2009) 0.93

Therapeutic cancer vaccines on trial. Nat Biotechnol (2002) 0.76

Clinical development of therapeutic recombinant proteins. Biotechniques (2003) 0.75